These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
147 related items for PubMed ID: 1096574
1. Indications of piribedil in L-DOPA-treated parkinsonian patients: physiopathologic implications. Rondot P, Bathien N, Dumas JL. Adv Neurol; 1975; 9():373-81. PubMed ID: 1096574 [No Abstract] [Full Text] [Related]
2. Action of piribedil in Parkinson's disease: I.V. test and oral treatment. Emile J, Chanelet J, Truelle JL, Bastard J. Adv Neurol; 1975; 9():409-13. PubMed ID: 1096577 [No Abstract] [Full Text] [Related]
3. [Piribedil in the treatment of Parkinson disease (author's transl)]. Nardini M, Sciannandrone R, Fieschi C, De Simone G. Riv Patol Nerv Ment; 1975; 96(2):103-10. PubMed ID: 778998 [Abstract] [Full Text] [Related]
4. Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism. Rinne UK, Sonninen V, Marttila R. Adv Neurol; 1975; 9():383-92. PubMed ID: 1096575 [Abstract] [Full Text] [Related]
5. [Piribedil, dopaminergic agonist. Prolonged clinical and electrophysiological study in 60 parkinsonian patients (author's transl)]. Truelle JL, Chanelet J, Bastard J, Six P, Emile J. Nouv Presse Med; 1977 Oct 08; 6(33):2987-90. PubMed ID: 22844 [Abstract] [Full Text] [Related]
8. Piribedil therapy in Parkinson's disease. Use of the drug in the retard form. Mentenopoulos G, Katsarou Z, Bostantjopoulou S, Logothetis J. Clin Neuropharmacol; 1989 Feb 08; 12(1):23-8. PubMed ID: 2713865 [Abstract] [Full Text] [Related]
10. [Long-term clinical and electrophysiological study of a new dopaminergic agonist in 54 patients with parkinsonism]. Truelle JL, Chanelet J, Bastard J, Six P, Emile J. Sem Hop Ther; 1977 Nov 08; 53(9):453-6. PubMed ID: 341320 [No Abstract] [Full Text] [Related]
13. Piribedil--an oral dopamine agonist for treatment of Parkinson's disease. Sweet RD, Wasterlain C, McDowell FH. Trans Am Neurol Assoc; 1974 Nov 08; 99():258-60. PubMed ID: 4463553 [No Abstract] [Full Text] [Related]
14. Early detection of L-dopa response in parkinsonian patients with a standardized tracking test. Albani C, Buck A. Adv Neurol; 1993 Nov 08; 60():386-9. PubMed ID: 8420158 [No Abstract] [Full Text] [Related]
15. Clonidine and the anti-parkinsonian response to L-DOPA or piribedil. Shoulson I, Chase TN. Neuropharmacology; 1976 Jan 08; 15(1):25-7. PubMed ID: 768802 [No Abstract] [Full Text] [Related]
16. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study. Suwantamee J, Nidhinandana S, Srisuwananukorn S, Laptikultham S, Pisarnpong A, Chankrachang S, Bundhukul A. J Med Assoc Thai; 2004 Nov 08; 87(11):1293-300. PubMed ID: 15825702 [Abstract] [Full Text] [Related]
17. Piribedil (ET 495) in the treatment of Parkinson's disease combined with amantadine or levodopa. Callaghan N, Fitzpatrick E, O'Mahony JB. Acta Neurol Scand; 1975 Sep 08; 52(3):179-86. PubMed ID: 1098359 [Abstract] [Full Text] [Related]
20. [Study of the M-H response, of the silent period and of post-tetanic potentiation in subjects with Parkinson's disease during treatment with L-dopa or Madopar]. Ferro Milone F, Lorizio A, Nordera G. Riv Neurol; 1975 Sep 08; 45(2):236-46. PubMed ID: 1179114 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]